Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APEX1 | P27695 | 1/20 | 1.00 |
| ▸ | PLCG2 | P16885 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.61 |
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
| ▸ | RAB9A | P51151 | 2/20 | 0.61 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.61 |
| ▸ | FBP1 | P09467 | 10/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1277212 | 1.00 | APEX1 (1.00) | APEX1PLCG2MAPTMAPK1NPC1 | |
| SCHEMBL3726872 | 0.91 | APEX1 (0.82) | APEX1PLCG2MAPTMAPK1NPC1 | |
| SCHEMBL1653052 | 0.86 | APEX1 (0.76) | APEX1PLCG2MAPTMAPK1NPC1 | |
| SCHEMBL28522107 | 0.82 | APEX1 (0.70) | APEX1PLCG2MAPTMAPK1NPC1 | |
| SCHEMBL6215530 | 0.82 | APEX1 (0.70) | APEX1PLCG2MAPTMAPK1NPC1 | |
| SCHEMBL1277489 | 0.82 | APEX1 (0.70) | APEX1PLCG2MAPTMAPK1NPC1 | |
| SCHEMBL1654091 | 0.82 | APEX1 (0.69) | APEX1PLCG2MAPTMAPK1NPC1 | |
| SCHEMBL21639494 | 0.81 | APEX1 (0.68) | APEX1PLCG2MAPTMAPK1NPC1 | |
| SCHEMBL27942805 | 0.81 | APEX1 (0.68) | APEX1PLCG2MAPTMAPK1NPC1 | |
| SCHEMBL1016404 | 0.79 | APEX1 (0.65) | APEX1PLCG2MAPTMAPK1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250049812-A1 | Compounds that Inhibit Necroptosis and Their Preparation Methods | SHANGHAI INST ORGANIC CHEMISTRY CAS (CN) | 2025-02-13 | — | — | US | disclosed |
| EP-4403557-A1 | COMPOUND THAT INHIBITS PROGRAMMED CELL NECROSIS, AND PREPARATION METHOD THEREFOR | Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences (CN) | 2024-07-24 | — | — | EP | disclosed |
| EP-1841762-A1 | SUBSTITUTED INDOLES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE | Aventis Pharma S.A. (FR) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006061493-A1 | SUBSTITUTED INDOLES, COMPOSITIONS CONTAINING THEM, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE | AVENTIS PHARMA S.A. (FR) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250049812-A1 | Compounds that Inhibit Necroptosis and Their Preparation Methods | RIPK1, RIPK3, RIPK4 | APEX1 1876/4885PLCG2 3282/4885MAPT 3176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.